The drugs currently used for the treatment of NAFLD, such as insulin sensitizer pioglitazone, farnesoid X receptor agonist obeticholic acid, and the thyroid hormone receptor THRβ agonist Resmetirom, target various pathways. Here, THRB is linked to metabolic dysfunction-associated steatotic liver disease.